Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the transaction, the director directly owned 366,682 shares in the company, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Stock Up 0.3%
Shares of NASDAQ JAZZ traded up $0.70 during midday trading on Monday, hitting $244.17. 861,484 shares of the stock traded hands, compared to its average volume of 983,015. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $246.07. The business has a 50 day moving average price of $228.38 and a two-hundred day moving average price of $195.43. The company has a market cap of $15.34 billion, a PE ratio of -12,202.40, a P/E/G ratio of 0.21 and a beta of 0.32.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion during the quarter. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.
Hedge Funds Weigh In On Jazz Pharmaceuticals
Analysts Set New Price Targets
JAZZ has been the subject of a number of recent research reports. Truist Financial set a $256.00 price objective on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, June 9th. Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, June 29th. Royal Bank Of Canada lifted their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. TD Cowen upped their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $246.06.
Check Out Our Latest Stock Analysis on JAZZ
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
- KBR Insiders Are Buying While the Market Misreads Its Spinoff
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
